Component

Non-HDL cholesterol concentration

Non-HDL cholesterol concentration. Experimental scope belongs to the associated record.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Non-HDL cholesterol differences in the 32-person trial were trends at weeks 8 and 12 and reached significance at week 16 (P=0.042).

    Pantethine → Non-HDL cholesterol concentration source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    false
    evidence_location
    Primary indexed abstract; full article retrieval was unavailable.
    experimental_model
    Randomized triple-blind placebo- and diet-controlled trial in 32 adults eligible for statin therapy under the study criteria
    exposure
    Pantethine 600 mg/day for weeks 1–8 and 900 mg/day for weeks 9–16.
    limitations
    Small short trial with industry-associated authors and surrogate outcomes; not evidence that pantothenic acid has the same effects or that events or mortality improve.
    nutrient_topic
    Pantothenic acid (vitamin B5) research collection; topical membership is not evidence of a direct dietary effect. · Pantothenate (vitamin B5)
    organism
    Homo sapiens
    plain_language
    The broader non-HDL marker reached statistical significance only at the later measurement.
    primary_references
    [b5-clin-evans2014] Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. (2014). https://pubmed.ncbi.nlm.nih.gov/24600231/ DOI: 10.2147/vhrm.s57116
    tissue_or_cell_type
    Circulating lipids

    Pantothenic acid (vitamin B5): coenzyme A, deficiency and nutrient interactions (2026-09-17) · lines 1425–1437

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized triple-blind placebo- and diet-controlled trial in 32 adults eligible for statin therapy under the study criteria · source_derived_draft · unverified_draft

    ### b5-clin-pantethine-nonhdl-2014 Non-HDL cholesterol differences in the 32-person trial were trends at weeks 8 and 12 and reached significance at week 16 (P=0.042). Condition category: normal nutrient_topic: Pantothenic acid (vitamin B5) research collection; topical membership is not evidence of a direct dietary effect. plain_language: The broader non-HDL marker reached statistical significance only at the later measurement. organism: Homo sapiens tissue_or_cell_type: Circulating lipids experimental_model: Randomized triple-blind placebo- and diet-controlled trial in 32 adults eligible for statin therapy under the study criteria limitations: Small short trial with industry-associated authors and surrogate outcomes; not evidence that pantothenic acid has the same effects or that events or mortality improve. exposure: Pantethine 600 mg/day for weeks 1–8 and 900 mg/day for weeks 9–16. cross_nutrient: false evidence_location: Primary indexed abstract; full article retrieval was unavailable. [b5-clin-evans2014] Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. (2014). https://pubmed.ncbi.nlm.nih.gov/24600231/ DOI: 10.2147/vhrm.s57116
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. A median dose of 3.5 grams per day of oat beta-glucan significantly lowered LDL-cholesterol by -0.19 with 95% CI -0.23 to -0.14 mmol/l, non-HDL-cholesterol by -0.20 with 95% CI -0.26 to -0.15 mmol/l and apoB by -0.03 with 95% CI -0.05 to -0.02 g/l compared with control interventions, and there was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol with I-squared of 79% and non-HDL-cholesterol with I-squared of 99%.

    Oat mixed-linkage beta-(1->3)/(1->4)-glucan → Circulating apolipoprotein B concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/glucan-research/27724985.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3", "start_char": 0, "end_char": 1647, "text_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3"}
    experimental_model
    Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants
    exposure
    Diets enriched with oat beta-glucan at a median 3.5 grams per day for at least three weeks
    limitations
    Considerable unexplained heterogeneity, with I-squared of 79 percent for LDL and 99 percent for non-HDL cholesterol. These are pooled estimates, not the expected effect of any particular product.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Human
    plain_language
    The particle count falls too, not just the cholesterol carried in it.
    primary_references
    [bg-p27724985] The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. (2016). https://pubmed.ncbi.nlm.nih.gov/27724985/ DOI: 10.1017/s000711451600341x
    tissue_or_cell_type
    Serum lipoproteins

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 502–513

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants · source_derived_draft · unverified_draft

    ### bg-apob-and-non-hdl-move-too A median dose of 3.5 grams per day of oat beta-glucan significantly lowered LDL-cholesterol by -0.19 with 95% CI -0.23 to -0.14 mmol/l, non-HDL-cholesterol by -0.20 with 95% CI -0.26 to -0.15 mmol/l and apoB by -0.03 with 95% CI -0.05 to -0.02 g/l compared with control interventions, and there was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol with I-squared of 79% and non-HDL-cholesterol with I-squared of 99%. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: The particle count falls too, not just the cholesterol carried in it. organism: Human tissue_or_cell_type: Serum lipoproteins experimental_model: Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants limitations: Considerable unexplained heterogeneity, with I-squared of 79 percent for LDL and 99 percent for non-HDL cholesterol. These are pooled estimates, not the expected effect of any particular product. exposure: Diets enriched with oat beta-glucan at a median 3.5 grams per day for at least three weeks evidence_span: {"source_cache": "artifacts/glucan-research/27724985.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3", "start_char": 0, "end_char": 1647, "text_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3"} [bg-p27724985] The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. (2016). https://pubmed.ncbi.nlm.nih.gov/27724985/ DOI: 10.1017/s000711451600341x
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards